| Literature DB >> 25921828 |
Carlos López-Abarrategui1, Christine McBeth, Santi M Mandal, Zhenyu J Sun, Gregory Heffron, Annia Alba-Menéndez, Ludovico Migliolo, Osvaldo Reyes-Acosta, Mónica García-Villarino, Diego O Nolasco, Rosana Falcão, Mariana D Cherobim, Simoni C Dias, Wolfgang Brandt, Ludger Wessjohann, Michael Starnbach, Octavio L Franco, Anselmo J Otero-González.
Abstract
Antimicrobial peptides form part of the first line of defense against pathogens for many organisms. Current treatments for fungal infections are limited by drug toxicity and pathogen resistance. Cm-p5 (SRSELIVHQRLF), a peptide derived from the marine mollusk Cenchritis muricatus peptide Cm-p1, has a significantly increased fungistatic activity against pathogenic Candida albicans (minimal inhibitory concentration, 10 µg/ml; EC50, 1.146 µg/ml) while exhibiting low toxic effects against a cultured mammalian cell line. Cm-p5 as characterized by circular dichroism and nuclear magnetic resonance revealed an α-helical structure in membrane-mimetic conditions and a tendency to random coil folding in aqueous solutions. Additional studies modeling Cm-p5 binding to a phosphatidylserine bilayer in silico and isothermal titration calorimetry using lipid monophases demonstrated that Cm-p5 has a high affinity for the phospholipids of fungal membranes (phosphatidylserine and phosphatidylethanolamine), only moderate interactions with a mammalian membrane phospholipid, low interaction with ergosterol, and no interaction with chitin. Adhesion of Cm-p5 to living C. albicans cells was confirmed by fluorescence microscopy with FITC-labeled peptide. In a systemic candidiasis model in mice, intraperitoneal administration of Cm-p5 was unable to control the fungal kidney burden, although its low amphiphaticity could be modified to generate new derivatives with improved fungicidal activity and stability. © FASEB.Entities:
Keywords: Candida albicans; antimicrobial peptide; systemic candidiasis
Mesh:
Substances:
Year: 2015 PMID: 25921828 PMCID: PMC4763977 DOI: 10.1096/fj.14-269860
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191